Evidence map›Paper›PMID 35784296›Full record

ArticleFrontiers in immunology2022

Liver Fibrosis in Primary Sjögren's Syndrome.

Theodoros Androutsakos, Theodoros A Voulgaris, Athanasios-Dimitrios Bakasis, Maria-Loukia Koutsompina, Loukas Chatzis, Ourania D Argyropoulou, Vasilis Pezoulas, Dimitrios I Fotiadis, George Papatheodoridis, Athanasios G Tzioufas and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Theodoros AndroutsakosDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Theodoros A VoulgarisDepartment of Gastroenterology, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
Athanasios-Dimitrios BakasisDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Maria-Loukia KoutsompinaDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Loukas ChatzisDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Ourania D ArgyropoulouDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Vasilis PezoulasUnit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.
Dimitrios I FotiadisUnit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.
George PapatheodoridisDepartment of Gastroenterology, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
Athanasios G TzioufasDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Andreas V GoulesDepartment of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRUniversity of Ioannina · GRLaiko General Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients. Methods: Consecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE. Results: Fifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30-81) and 55 (19-86) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, Conclusion: Liver fibrosis among pSS patients is most likely not attributed to the disease

Indexed as

Diabetes Mellitus, Type 2Elasticity Imaging TechniquesNon-alcoholic Fatty Liver DiseaseSjogren's SyndromeHumansLiver CirrhosisMiddle Agedliver fibrosisliver steatosisnon-alcoholic fatty liver diseaseSjögren’s syndrometransient elastography

Identifiers

PMID35784296
PMCPMC9240196
OpenAlexW4282930971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.